NRD
FDMT icon

Nebula Research & Development’s 4D Molecular Therapeutics FDMT Stock Holding History

Nebula Research & Development’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,981
Closed -$41.9K – 1019
2025
Q1 		$41.9K Sell
12,981
-10,083
-44% -$47.5K ﹤0.01% 921
2024
Q4 		$128K Buy
23,064
+6,277
+37% +$49.3K 0.02% 845
2024
Q3 		$181K Buy
+16,787
New +$279K 0.02% 840

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nebula Research & Development's FDMT Position: Q2 2025 in Review

Nebula Research & Development sold out of 4D Molecular Therapeutics (FDMT) in Q2 2025, closing a stake of 12,981 shares — an estimated $41.9K sold.

Nebula Research & Development first reported a position in FDMT in Q3 2024 and held it in 3 quarters. The position peaked at $181K in Q3 2024. 120 funds tracked by Wall St. Rank hold FDMT as of Q2 2025.

  • Nebula Research & Development reported no remaining 4D Molecular Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,981 4D Molecular Therapeutics shares in Q2 2025, an estimated $41.9K.
  • Nebula Research & Development first reported a position in 4D Molecular Therapeutics in Q3 2024 and held it in 3 quarters.
  • Nebula Research & Development's 4D Molecular Therapeutics position peaked at $181K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.